• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.

作者信息

Symonds Lynn K, Davidson Nancy E

机构信息

Fred Hutchinson Cancer Center, Seattle, WA, USA.

Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.

出版信息

J Natl Cancer Inst. 2023 Nov 8;115(11):1240-1242. doi: 10.1093/jnci/djad111.

DOI:10.1093/jnci/djad111
PMID:37480258
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10637028/
Abstract
摘要

相似文献

1
Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.我们到了吗？绝经后早期激素受体阳性乳腺癌女性内分泌治疗的最佳持续时间。
J Natl Cancer Inst. 2023 Nov 8;115(11):1240-1242. doi: 10.1093/jnci/djad111.
2
Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.辅助来曲唑和他莫昔芬单独或序贯用于激素受体阳性乳腺癌绝经后妇女：BIG 1-98 试验的长期随访。
J Clin Oncol. 2019 Jan 10;37(2):105-114. doi: 10.1200/JCO.18.00440. Epub 2018 Nov 26.
3
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.体细胞驱动改变与绝经后、激素受体阳性、HER2 阴性早期乳腺癌患者预后的相关性：BIG 1-98 随机临床试验的二次分析。
JAMA Oncol. 2018 Oct 1;4(10):1335-1343. doi: 10.1001/jamaoncol.2018.1778.
4
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.来曲唑与他莫昔芬在绝经后早期乳腺癌女性中的比较。
N Engl J Med. 2005 Dec 29;353(26):2747-57. doi: 10.1056/NEJMoa052258.
5
The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.绝经后女性激素受体阳性乳腺癌的乳腺癌连续体：聚焦芳香化酶抑制剂的不断演变的管理选择
Ann Oncol. 2008 Jan;19(1):16-27. doi: 10.1093/annonc/mdm282. Epub 2007 Aug 9.
6
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.国际乳腺癌研究组（BIG）1-98研究的设计、实施与分析：一项随机、双盲、III期研究，比较来曲唑与他莫昔芬作为绝经后激素受体阳性早期乳腺癌患者辅助内分泌治疗的疗效。
Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.
7
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.从加拿大的角度看，来曲唑与他莫昔芬作为激素受体阳性早期乳腺癌绝经后女性初始辅助治疗的成本效益
Breast Cancer Res Treat. 2008 Apr;108(3):375-87. doi: 10.1007/s10549-007-9607-7. Epub 2007 Jul 26.
8
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.降低绝经后女性他莫昔芬治疗结束后乳腺癌复发风险。
Clin Ther. 2007 Aug;29(8):1535-47. doi: 10.1016/j.clinthera.2007.08.013.
9
Update of the BIG 1-98 Trial: where do we stand?BIG 1-98 试验更新：我们现在处于什么位置？
Breast. 2009 Oct;18 Suppl 3:S78-82. doi: 10.1016/S0960-9776(09)70278-4.
10
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.根据中心评估的ERBB2状态，来曲唑与他莫昔芬作为绝经后内分泌反应性早期乳腺癌女性辅助治疗的比较：BIG 1-98随机试验的补充结果
Lancet Oncol. 2008 Jan;9(1):23-8. doi: 10.1016/S1470-2045(07)70386-8. Epub 2007 Dec 20.

本文引用的文献

1
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.十年随访更新：NRG 肿瘤学/美国国家外科辅助乳腺和肠道项目 B-42 随机试验：早期乳腺癌中延长来曲唑治疗。
J Natl Cancer Inst. 2023 Nov 8;115(11):1302-1309. doi: 10.1093/jnci/djad078.
2
Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.采用 70 基因签名超低分类法限制绝经后乳腺癌患者的全身内分泌过度治疗。
Breast Cancer Res Treat. 2022 Jul;194(2):265-278. doi: 10.1007/s10549-022-06618-z. Epub 2022 May 19.
3
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.早期乳腺癌辅助内分泌和化疗的生物标志物：ASCO 指南更新。
J Clin Oncol. 2022 Jun 1;40(16):1816-1837. doi: 10.1200/JCO.22.00069. Epub 2022 Apr 19.
4
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.来曲唑延长辅助治疗用于绝经后早期乳腺癌患者的多中心、开放标签、随机、3 期临床试验
Lancet Oncol. 2021 Oct;22(10):1458-1467. doi: 10.1016/S1470-2045(21)00352-1. Epub 2021 Sep 17.
5
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.绝经后乳腺癌辅助芳香化酶抑制剂治疗的持续时间。
N Engl J Med. 2021 Jul 29;385(5):395-405. doi: 10.1056/NEJMoa2104162.
6
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.临床治疗评分5（CTS5）在评估未经选择的非试验性早期雌激素受体阳性乳腺癌患者晚期复发风险中的临床有效性。
Breast Cancer Res Treat. 2021 Feb;186(1):115-123. doi: 10.1007/s10549-020-06013-6. Epub 2020 Nov 21.
7
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).阿贝西利联合内分泌治疗用于 HR+、HER2-、淋巴结阳性、高危、早期乳腺癌的辅助治疗（monarchE）。
J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20.
8
Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.乳腺癌指数与辅助他莫昔芬治疗更多？（aTTom）试验中治疗的乳腺癌患者延长内分泌治疗获益预测。
Ann Oncol. 2019 Nov 1;30(11):1776-1783. doi: 10.1093/annonc/mdz289.
9
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.来曲唑在基于芳香化酶抑制剂的治疗后在绝经后乳腺癌中的应用（NRG 肿瘤学/NSABP B-42）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet Oncol. 2019 Jan;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. Epub 2018 Nov 30.
10
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.激素受体阳性乳腺癌妇女的辅助内分泌治疗：ASCO 临床实践指南更新焦点。
J Clin Oncol. 2019 Feb 10;37(5):423-438. doi: 10.1200/JCO.18.01160. Epub 2018 Nov 19.